Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Biosimilar vs Lucentis in Diabetic Macular Edema
NCT06305416Phase 3Completed
- Sponsor
- Incepta Pharmaceuticals Ltd.
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in diabetic macular edema (DME), sponsored by Incepta Pharmaceuticals Ltd.. Started Mar 2024; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06305416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305416.